MedDataX Logo

BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration

NCT ID: NCT04690062

Last Updated: 2020-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-25

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done.

Procedure included intravitreal injection of Brolucizumab (BEOVU®, Genen-tech, South Francisco, CA)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dystrophy, Retinal

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

macular degeneration BEOVU RETINAL DYSTROPHY

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BEOVU

Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months

Group Type EXPERIMENTAL

Brolucizumab-Dbll

Intervention Type DRUG

intravitreal injection of Brolucizumab (BEOVU)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brolucizumab-Dbll

intravitreal injection of Brolucizumab (BEOVU)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BEOVU

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Dystrophy-Related macular neovascularization degeneration

Exclusion Criteria

* age related macular degeneration , other causes of macular neovascularization degeneration
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Benha University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tarek Roshdy mohamed Mahgoub ELhamaky

Lecturer of ophthalmology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tarek Elhamaky, MD

Role: PRINCIPAL_INVESTIGATOR

Benha university faculty of medicine , INMC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

INMC

Abu Dhabi, , United Arab Emirates

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Arab Emirates

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tarek R Elhamaky, MD

Role: CONTACT

Phone: +97126324200

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

TAREK R ELHAMAKY, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Hamaky7

Identifier Type: -

Identifier Source: org_study_id